SCHEMBL4658952

SCHEMBL4658952

CCCNC(=O)c1ccc[nH]1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.59
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.54
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244791 0.89 HDAC3 (0.61) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL2781925 0.87 KDM4E (0.61) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL29038565 0.86 HDAC3 (0.67) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL29038556 0.86 HDAC3 (0.67) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL4591341 0.83 HDAC3 (0.58) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL4591337 0.83 HDAC3 (0.58) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL13042362 0.82 HDAC3 (0.57) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL31672540 0.82 ALDH1A1 (0.55) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL14591099 0.81 KDM4E (0.55) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL31469605 0.81 KDM4E (0.55) KDM4EHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US claimed
CN-119585239-A Nucleic acid binding agents 斯特拉斯克莱德大学 2025-03-07 CN disclosed
US-7621992-B2 stabilizer for improve high optical density, clear color image, durability of printed images, waterproofing, lightfastness, gasfastness, environmental resistance, storage stability, and non-clogging of nozzles; thermal printing by a piezoelectric device SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-11-24 US disclosed
US-7621992-B2 stabilizer for improve high optical density, clear color image, durability of printed images, waterproofing, lightfastness, gasfastness, environmental resistance, storage stability, and non-clogging of nozzles; thermal printing by a piezoelectric device SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-11-24 US disclosed
EP-2001886-A2 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2008-12-17 EP disclosed
WO-2007103839-A2 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS SQSTM1, TFEB, BECN1 KDM4E 2987/4885HDAC3 78/4885HDAC4 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.